Abstract
Get full access to this article
View all access options for this article.
References
1.US Food and Drug Administration . Rare pediatric disease priority review vouchers, draft guidance for industry . https://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM423325.pdf. Published November 17 , 2014 . Accessed April 7, 2017 .
2.
Gaffney
A
Mezher
M
Brennan
Z.
Regulatory explainer: everything you need to know about FDA’s priority review vouchers. Regulatory Affairs Professionals Society . http://www.raps.org/Regulatory-Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-You-Need-to-Know-About-FDA%E2%80%99s-Priority-Review-Vouchers/#sthash.5Mrh1alX.dpuf. Published November 3 , 2016 . Accessed April 7, 2017 .
3.
Ridley
D.
Priority review vouchers . http://priorityreviewvoucher.org/. Published 2017 . Accessed April 7, 2017 .
4.US Food and Drug Administration . Fee for using a rare pediatric disease priority review voucher in fiscal year 2017 . https://www.federalregister.gov/documents/2016/09/30/2016-23624/fee-for-using-a-rare-pediatric-disease-priority-review-voucher-in-fiscal-year-2017. Published September 30 , 2016 . Accessed April 7, 2017 .
5.
Aurora
P
Romine
M
Daniel
G.
Are priority review vouchers the answer to incentivize drug development? Not so fast . http://healthaffairs.org/blog/2016/06/15/are-priority-review-vouchers-the-answer-to-incentivize-drug-development-not-so-fast/. Published June 15 , 2016 . Accessed April 7, 2017 .
6.
Brennan
Z.
Sanofi redeems $245M priority review voucher for type 2 diabetes treatment . http://www.raps.org/Regulatory-Focus/News/2016/02/22/24378/Sanofi-Redeems-245M-Priority-Review-Voucher-for-Type-2-Diabetes-Treatment/. Published February 22 , 2016 . Accessed April 7, 2017 .
7.
Tribble
SJ.
Are golden tickets that speed drugs through FDA worthwhile? http://www.npr.org/sections/health-shots/2016/09/29/495904450/are-golden-tickets-that-speed-drugs-through-fda-worthwhile. Published September 29 , 2016 . Accessed April 7, 2017 .